Revascularisation for Claudication: When is it indicated, when not? Markus Haumer Landesklinikum Baden-Mödling Austria
|
|
|
- Harold Golden
- 5 years ago
- Views:
Transcription
1 Revascularisation for Claudication: When is it indicated, when not? Markus Haumer Landesklinikum Baden-Mödling Austria
2 Disclosure Disclosure Speaker name: Markus Haumer, MD I have the following potential conflicts of interest to report: Consulting Employment in industry Stockholder of a healthcare company Owner of a healthcare company Other(s) I do not have any potential conflict of interest
3 What a claudicant faces RISK ADVERSE CARDIOVASCULAR EVENTS PREMATURE DEATH LIMB LOSS QUALITY QUALITY OF LIFE EXERTIONAL LEG PAIN ROLE FUNCTIONING
4 Too Much Sitting Increases Mortality Risk Lynch BM et al. Ann Int Med 2015: René Magritte (1951) Perspective I Evidence shows that sedentary behaviour contributes to All-cause death Cardiovascular death Cancer death Incidence of cardiovascular disease, cancer, and type 2 diabetes
5 Too Much Sitting Increases Mortality Risk Lynch BM et al. Ann Int Med 2015: Jacques-Louis David (1800) Madame Récamier Minimize the amount of time spent in prolonged sitting Break up long periods of sitting as often as possible Accumulate 150 to 300 minutes of moderate intensity physical activity or...equal..., each week.
6 ...but Johnny Walker is still alive!
7 Exertional Leg Symptoms Comorbidities in Claudicants Lumbar disc disease: 36% 1 Spinal stenosis: 11% 2 Hip arthritis 4% 2 Knee arthritis: 12% 1 1 McDermott MM et al. Circulation 2008;117: McDermott MM et al. J Vasc Surg 2005;42:
8 Chronic Limb Ischemia Definitions Fontaine Stage I IIa IIb III IV Rutherford Category Ankle Brachial Index Ankle Pressure [mmhg] (70) 0 Asympt. Claudication Critical Limb Ischemia
9 Rutherford RB et al. J Vasc Surg 1997;26: Fontaine Stage IIa Claudication Definitions IIb Rutherford Category Mild Completes treadmill exercise AP* after exercise >50mmHg but 20mmHg lower than resting value *AP...Ankle pressure Moderate Between Categories 1 and 3 Severe Cannot complete treadmill exercise and AP* after exercise <50mmHg
10 Fontaine Stage IIa Claudication Definitions IIb Rutherford Category ±500m Max. Walking Distance ±100m Quality of Life
11 Events in Claudicants 15 Year Study of Veterans Muluk JC et al. J Vasc Surg 2001;33: Mortality rate: 12% per year 2/3 due to heart disease Revascularisation rate: 18% after 10 years Minor amputations: <10% after 10 years Major amputations: <10% after 10 years
12 Chronic Limb Ischemia Management General principles I Ila Ilb III IV Lifestyle Modification Best Medical Treatment Exercise Revascularisation Prostanoids Local Therapy, Amputation
13 Treatment of Claudication Network of Aims and Options Survival Death Walking Capacity Quality of Life ABI
14 Treatment of Claudication Network of Aims and Options Supervised Exercise Best Medical Treatment Revascularisation
15 Treatment of Claudication Network of Aims and Options Survival Death Quality of Life Supervised Exercise Best Medical Treatment Revascularisation Walking Capacity ABI
16 Treatment of Claudication Network of Aims and Options Survival Death Quality of Life Supervised Exercise Best Medical Treatment Revascularisation Walking Capacity ABI
17 Treatment of Claudication Network of Aims and Options The relative benefits of these 3 strategies of care are not known because no multicenter clinical trials have directly compared these 3 strategies. Study of the comparative effectiveness of claudication treatment strategies is in the top 50 of all American health challenges. Murphy TP et al. Circulation 2012;125:130-9
18 Yusuf S Lancet 2002;360:2-3. Fonarow GC et al. Am J Cardiol 2000;85:10A-17A. Modification of Risk I Ila Ilb III IV Lifestyle Modification Best Medical Treatment Cumulative Relative Risk-Reduction Therapy RRR MACE/10a 40% Smoking 50% 20% ASS 25% 15% Statins 30% 10% LDL-C % 8% ACE-I / ARB 25% 6% ß-Blocker 25% 5%
19 NO BENEFIT HEPARIN / OAC GINKGO BILOBA VITAMIN E OMEGA-3-FA PADMA 28 GARLIC Best Medical Treatment Phlebotonics for venous insufficiency (Review) Improvement Martinez-Zapata MJ, Bonfill of Cosp Walking X, Moreno RM, VargasE, Distance Capellà D Thisisareprint of acochranereview, prepared and maintained bythecochranecollaboration and published in TheCochraneLibrary 2008, Issue4 POSSIBLE BENEFIT CILOSTAZOL HIGH DOSE STATINS NAFTIDROFURYL PENTOXIFYLLINE PROSTANOIDS RAMIPRIL JAMA 2013;309:
20 Treatment of Claudication Network of Aims and Options Survival Death Quality of Life neutral positive negative Supervised Exercise Best Medical Treatment Revascularisation Walking Capacity ABI
21 Exercise vs. Revascularisation 3 RCTs MIMIC Trial Mild to Moderate Intermittent Claudication EJVES 2008;36: CLEVER Study Claudication: Exercise Vs. Endoluminal Revascularization Circulation 2012;125: OMC + SE ± PTA n=127 (93 fem-pop; 34 aorto-iliac); ABI EP: ICD / AWD OMC + SE vs. OMC + PTA n=111 (aorto-iliac); ABI EP: PWT 2 EP: QoL IRONIC Trial Invasive Revascularization Or Not in IC Circulation 2014;130: OMC + HBE vs. OMC + PTA n=78 (mixed); ABI EP: PWT 2 EP: QoL [OMC... Optimal Medical Care, SE...Supervised Exercise; HABE...Home Based Exercise, ICD...Initial Caldication Distance; AWD...Absolute Walking Distance; PWT...Peak Walking Time]
22 Angioplasty Intermittent LINC Cases ABI (median): 0.48 Range: IQR: Intensity of Claudication: Severe (RB Category 3) Absolute (?) walking distance: 50 meters (IQR )
23 Exercise vs. Revascularisation 3 RCTs MIMIC Trial Mild to Moderate Intermittent Claudication EJVES 2008;36: CLEVER Study Claudication: Exercise Vs. Endoluminal Revascularization Circulation 2012;125: IRONIC Trial Invasive Revascularization Or Not in IC Circulation 2014;130: PTA confers benefit (p<0.05) SE is superior in PWT (p=0.04) Improvement in QoL is greater with PTA (n.s.) PTA improves QoL (p<0.01) and claudication distance (p=0.003) [OMC... Optimal Medical Care, SE...Supervised Exercise; HABE...Home Based Exercise, ICD...Initial Caldication Distance; AWD...Absolute Walking Distance; PWT...Peak Walking Time; QoL Quality of Life]
24 Giugliano G et al. Int J Cardiol 2013;167; Effects of lower extremity PTA on CV outcome in Claudicants PTA OMT PTA vs. OMT (non-randomized) 678 Claudicants ABI 0.9; 50%Stenosis 6/2007-6/2009 PTA-Group (n=264) ABI: 0.68 ± 0.19 RB-Category 3: 85%* MWD: 124 ± 306 meters* OMT-Group (n=215) ABI: 0.66 ± 0.17 RB-Category 3: 37%* MWD: 403 ± 532 meters* *p<0.001
25 Giugliano G et al. Int J Cardiol 2013;167; Effects of lower extremity PTA on CV outcome in Claudicants PTA OMT PTA vs. OMT (non-randomized) 678 Claudicants ABI 0.9; 50%Stenosis 6/2007-6/2009 PTA-Group (n=264) ABI: 0.68 ± 0.19 RB-Category 3: 85%* MWD: 124 ± 306 meters* OMT-Group (n=215) ABI: 0.66 ± 0.17 RB-Category 3: 37%* MWD: 403 ± 532 meters* *p<0.001
26 Survival in Intermittent Claudication Pooled Data Angioplasty Registry Survival (n=2.930) 1 yr 3 yr 5 yr PTA Rutherford RB et al. J Vasc Surg : Miura T et al. JEVT 2014;21:381-8.
27 Treatment of Claudication Network of Aims and Options Survival Death Quality of Life neutral positive negative Supervised Exercise Best Medical Treatment Revascularisation Walking Capacity ABI
28 Treatment of Claudication Network of Aims and Options Survival Death Quality of Life neutral positive negative Supervised Exercise Best Medical Treatment Revascularisation Walking Capacity ABI
29 Treatment of Claudication Network of Aims and Options Survival Death Quality of Life neutral positive negative Supervised Exercise Best Medical Treatment Revascularisation Walking Capacity ABI
30 Risks of Revascularisation Patient-Specific Factors TASC A TASC B TASC C TASC D FCR FCR FCR FCR FAILURE (F) COMPLICATION (C) RECURRENCE (R)
31 Risks of Revascularisation Risk Reduction Patient-Specific Factors TASC A TASC B TASC C TASC D FCR FCR FCR FCR CAREFUL SELECTION AND PREPARATION PATIENTS TREATING PHYSICIANS TREATMENT STRATEGY
32 Revascularisation for Claudication? YES PAD is cause of moderate / severe claudication or PAD is subcritical OMT is established SE is not available, feasible or successful Risk/Benefit-Ratio is adaequate NO Severe comorbidities Intolerance or non-adherence to antithrombotic therapy René Magritte (1934) La Modèle Rouge
33 Revascularisation for Claudication: When is it indicated, when not? Markus Haumer Landesklinikum Baden-Mödling Austria
Nurse and Technician Forum Part II Critical Limb Ischemia: Optimal care, an interdisciplinary challenge
L E I P Z I G I N T E R V E N T I O N A L C O U R S E 2017 Nurse and Technician Forum Part II Critical Limb Ischemia: Optimal care, an interdisciplinary challenge Markus Haumer Landesklinikum Baden-Mödling
John E. Campbell, MD. Assistant Professor of Surgery and Medicine Department of Vascular Surgery West Virginia University, Charleston Division
John E. Campbell, MD Assistant Professor of Surgery and Medicine Department of Vascular Surgery West Virginia University, Charleston Division John Campbell, MD For the 12 months preceding this CME activity,
Claudication Exercise vs. Endoluminal Revascularization
Claudication Exercise vs. Endoluminal Revascularization Anthony J. Comerota, MD, FACS, FACC Director, Jobst Vascular Institute Adjunct Professor of Surgery, University of Michigan Disclosures NIH Research
3-year results of the OLIVE registry:
3-year results of the OLIVE registry: A prospective multicenter study in patients with critical limb ischemia Osamu Iida, MD Kansai Rosai Hospital Cardiovascular Center Amagasaki, Hyogo, Japan Disclosure
ACC NY Cardiovascular Symposium
ACC NY Cardiovascular Symposium Peripheral Vascular Disease: Watch the Heart and the Brain Evolving Role of Exercise, ACE-Inhibitors, Interventional and Surgical Options Mark A. Creager, M.D President,
Claudication Treatment Comparative Effectiveness: 6 Month Outcomes from the CLEVER Study
Claudication Treatment Comparative Effectiveness: 6 Month Outcomes from the CLEVER Study Authors: Murphy TP, Cutlip DE, Regensteiner JG, Mohler ER, Cohen DC, Reynolds MR, Lewis BA, Cerezo J, Oldenburg
Treatment Strategies For Patients with Peripheral Artery Disease
Treatment Strategies For Patients with Peripheral Artery Disease Presented by Schuyler Jones, MD Duke University Medical Center & Duke Clinical Research Institute AHRQ Comparative Effectiveness Review
Medical Therapy of Peripheral Artery Disease
Medical Therapy of Peripheral Artery Disease Alvaro Alonso, MD Assistant Professor of Medicine Associate Director, Interven4onal Cardiology Fellowship Program Tulane University Heart & Vascular Ins4tute
Evidence-Based Optimal Treatment for SFA Disease
Evidence-Based Optimal Treatment for SFA Disease Endo first Don t burn surgical bridge Don t stent if possible Javairiah Fatima, MD Assistant Professor of Surgery Division of Vascular and Endovascular
Medical Therapy for Peripheral Artery Disease
Medical Therapy for Peripheral Artery Disease Beau M. Hawkins, MD, FSCAI University of Oklahoma Health Sciences Center, Oklahoma City, OK Sahil A. Parikh, MD, FSCAI Columbia University Medical Center,
Medical Management of Vascular Disease KEITH E SWANSON MD ND ACADEMY OF FAMILY PHYSICIANS FAMILY MEDICINE UPDATE JANUARY 2017
Medical Management of Vascular Disease KEITH E SWANSON MD ND ACADEMY OF FAMILY PHYSICIANS FAMILY MEDICINE UPDATE JANUARY 2017 Objectives 1. Appreciate the long term implications of PAD 2. Appreciate the
DCB in my practice: How the evidence influences my strategy. Yang-Jin Park
DCB in my practice: How the evidence influences my strategy Yang-Jin Park Associate Professor Division of Vascular Surgery, Department of Surgery Samsung Medical Center Sungkyunkwan University School of
Early Identification of PAD: Evidence to Refute USPSTF Position on Screening
Early Identification of PAD: Evidence to Refute USPSTF Position on Screening Mehdi H. Shishehbor, DO, MPH, PhD Director Endovascular Services Interventional Cardiology & Vascular Medicine Department of
PAD and CRITICAL LIMB ISCHEMIA: EVALUATION AND TREATMENT 2014
PAD and CRITICAL LIMB ISCHEMIA: EVALUATION AND TREATMENT 2014 Van Crisco, MD, FACC, FSCAI First Coast Heart and Vascular Center, PLLC Jacksonville, FL 678-313-6695 Conflict of Interest Bayer Healthcare
Peripheral Artery Disease Role of Exercise, Endovascular and Surgical Options
Peripheral Artery Disease Role of Exercise, Endovascular and Surgical Options Jeffrey W. Olin, D.O., F.A.C.C., F.A.H.A. Professor of Medicine (Cardiology) Director of Vascular Medicine & the Vascular Diagnostic
Comparing endoluminal bypass to open fem-pop bypasses; Final 1-year results of the SUPERB trial
Comparing endoluminal bypass to open fem-pop bypasses; Final 1-year results of the SUPERB trial Michel Reijnen Rijnstate Hospital Arnhem, The Netherlands Disclosure Speaker name: Michel Reijnen I have
Hybrid surgical treatment of bilateral aorto-femoral occlusion: a clinical case
Hybrid surgical treatment of bilateral aorto-femoral occlusion: a clinical case Chernyavskiy M.,MD,PhD, Chernova D., Zherdev N., Chernov A. Almazov National Medical Research Centre, St.Petersburg, Russia
Maximally Invasive Vascular Surgery for the Treatment of Critical Limb Ischemia
Maximally Invasive Vascular Surgery for the Treatment of Critical Limb Ischemia Traci A. Kimball, MD Department of Surgery Grand Rounds Septemember 13, 2010 Overview Defining Critical Limb Ischemia Epidemiology
Practical Point in Diabetic Foot Care 3-4 July 2017
Diabetic Foot Ulcer : Role of Vascular Surgeon Practical Point in Diabetic Foot Care 3-4 July 2017 Supapong Arworn, MD Division of Vascular and Endovascular Surgery Department of Surgery, Chiang Mai University
John E. Campbell, MD Assistant Professor of Surgery and Medicine Department of Vascular Surgery West Virginia University, Charleston Division
John E. Campbell, MD Assistant Professor of Surgery and Medicine Department of Vascular Surgery West Virginia University, Charleston Division John Campbell, MD For the 12 months preceding this CME activity,
Peripheral Arterial Disease: Objectives. Disclosure. Definition: Peripheral Arterial Disease (PAD)
Geriatric Grand Rounds Tuesday, April 21, 2009 12:00 noon Dr. Bill Black Auditorium Glenrose Rehabilitation Hospital In keeping with Glenrose Rehabilitation Hospital policy, speakers participating in this
The Crack and Pave technique for highly resistant calcified lesions. Manuela Matschuck MD University Hospital Leipzig Department Angiology
The Crack and Pave technique for highly resistant calcified lesions Manuela Matschuck MD University Hospital Leipzig Department Angiology Disclosure Speaker name: Dr. med. Manuela Matschuck I have the
Objective assessment of CLI patients Hemodynamic parameters
Objective assessment of CLI patients Hemodynamic parameters Worth anything in end stage patients? Marianne Brodmann Angiology, Medical University Graz, Austria Disclosure Speaker name: Marianne Brodmann
Peripheral Arterial Disease Extremity
Peripheral Arterial Disease Lower Extremity 05 Contributor Dr Steven Chong Advisors Dr Ashish Anil Dr Tay Jam Chin Introduction Risk Factors Clinical Presentation Classification History PHYSICAL examination
Peripheral Arterial Disease (PAD): Presentation, Diagnosis, and Treatment
Peripheral Arterial Disease (PAD): Presentation, Diagnosis, and Treatment Prepared and Presented by Jon Manocchio, Pharm D Blanchard Valley Hospital October 2011 Introduction PAD is a condition that is
Clinical Approach to CLI and Related Diagnostics: What You Need to Know
Clinical Approach to CLI and Related Diagnostics: What You Need to Know Ido Weinberg, MD Assistant Professor of Medicine Harvard Medical School Massachusetts General Hospital None Disclosures Critical
Comparison Of Primary Long Stenting Versus Primary Short Stenting For Long Femoropopliteal Artery Disease (PARADE)
Comparison Of Primary Long Stenting Versus Primary Short Stenting For Long Femoropopliteal Artery Disease (PARADE) Young-Guk Ko, M.D. Severance Cardiovascular Hospital, Yonsei University Health System,
Is there enough evidence for DAPT after endovascular intervention for PAOD?
Is there enough evidence for DAPT after endovascular intervention for PAOD? Prof. I. Baumgartner Head Clinical & Interventional Angiology University Hospital Bern Disclosure Speaker name:...i. Baumgartner...
Current Vascular and Endovascular Management in Diabetic Vasculopathy
Current Vascular and Endovascular Management in Diabetic Vasculopathy Yang-Jin Park Associate professor Vascular Surgery, Samsung Medical Center Sungkyunkwan University School of Medicine Peripheral artery
Interventional Treatment First for CLI
Interventional Treatment First for CLI Patrick Alexander, MD, FACC, FSCAI Interventional Cardiology Medical Director, Critical Limb Clinic Providence Heart Institute, Southfield MI 48075 Disclosures Consultant
LDL Cholesterol Lowering with Evolocumab and Outcomes in Patients with Peripheral Artery Disease: Insights from the FOURIER Trial
LDL Cholesterol Lowering with Evolocumab and Outcomes in Patients with Peripheral Artery Disease: Insights from the FOURIER Trial Marc P. Bonaca, Patrice Nault, Robert P. Giugliano, Anthony C. Keech, Armando
Koen Keirse, MD RZ Tienen, Belgium
Clinical Benefits of the Vanguard IEP Peripheral Balloon Angioplasty System with Integrated Embolic Protection from the ENTRAP Study Koen Keirse, MD RZ Tienen, Belgium Disclosure Speaker name: Koen Keirse...
Case Study: Chris Arden. Peripheral Arterial Disease
Case Study: Chris Arden Peripheral Arterial Disease Patient Presentation Diane is a 65-year-old retired school teacher She complains of left calf pain when walking 50 metres; the pain goes away after she
The results of EVT for Chronic Aortic Occlusion - a multicenter retrospective study - Taku Kato, MD Rakuwakai Otowa Hospital, Kyoto, Japan
The results of EVT for Chronic Aortic Occlusion - a multicenter retrospective study - Taku Kato, MD Rakuwakai Otowa Hospital, Kyoto, Japan COI disclosure Disclosure Speaker name: Taku Kato... I have the
ISMJ International SportMed Journal
ISMJ International SportMed Journal FIMS Position Statement 2011 Exercise training in Peripheral Arterial Disease *Professor Arno Schmidt-Trucksäss, MD, MA Division Sports and Exercise Medicine, Institute
Most Important Clinical Trials of the Past Decade in Vascular Intervention
Most Important Clinical Trials of the Past Decade in Vascular Intervention Andrew J. P. Klein, MD, FACC, FSCAI Interventional Cardiology Vascular and Endovascular Medicine Piedmont Heart Institute Atlanta,
Garland Green, MD Interventional Cardiologist. Impact of PAD: Prevalence, Risk Factors, Testing, and Medical Management
Garland Green, MD Interventional Cardiologist Impact of PAD: Prevalence, Risk Factors, Testing, and Medical Management Peripheral Arterial Disease Affects over 8 million Americans Affects 12% of the general
Femoropopliteal Above-Knee Bypass: The True Results
Femoropopliteal Above-Knee Bypass: The True Results Lise Pyndt Jørgensen, Camilla Rasmussen & Torben V Schroeder Rigshospitalet and University of Copenhagen, DENMARK Treatment options in the femoropopliteal
Promise and limitations of DCB in long lesions What Have we Learned from Clinical Trials? Ramon L. Varcoe, MBBS, MS, FRACS, PhD
Promise and limitations of DCB in long lesions What Have we Learned from Clinical Trials? Ramon L. Varcoe, MBBS, MS, FRACS, PhD Associate Professor of Vascular Surgery University of New South Wales Sydney,
2-YEAR DATA SUPERA POPLITEAL REAL WORLD
2-YEAR DATA SUPERA POPLITEAL REAL WORLD Enrique M. San Norberto. Angiology and Vascular Surgery. Valladolid University Hospital. Valladolid. Spain. Disclosure Speaker name: ENRIQUE M. SAN NORBERTO I have
Larry Diaz, MD, FSCAI Mehdi H. Shishehbor, DO, FSCAI
PAD Diagnosis Larry Diaz, MD, FSCAI Metro Health / University of Michigan Health, Wyoming, MI Mehdi H. Shishehbor, DO, FSCAI University Hospitals Harrington Heart & Vascular Institute, Cleveland, OH PAD:
What s New in the Management of Peripheral Arterial Disease
What s New in the Management of Peripheral Arterial Disease Sibu P. Saha, MD, MBA Professor of Surgery Chairman, Directors Council Gill Heart Institute University of Kentucky Lexington, KY Disclosure My
Disclosures. TASC, AHA, SVS: What s Happening with the Guidelines? How Are They Relevant? Purpose of Practice Guidelines
TASC, AHA, SVS: What s Happening with the Guidelines? How Are They Relevant? Michael S. Conte MD, FACS Division of Vascular and Endovascular Surgery Co-Director, Heart and Vascular Center UCSF Medical
Vascular screening in diabetic patients: how aggressive should we be and when to intervene?
Vascular screening in diabetic patients: how aggressive should we be and when to intervene? Roberto Ferraresi Peripheral Interventional Unit Bergamo Italy Disclosure Speaker name: ROBERTO FERRARESI X X
Drug-Coated Balloon Treatment for Patients with Intermittent Claudication: Insights from the IN.PACT Global Full Clinical Cohort
Drug-Coated Balloon Treatment for Patients with Intermittent Claudication: Insights from the IN.PACT Global Full Clinical Cohort a.o. Univ. Prof. Dr. Marianne Brodmann Medical University of Graz Graz,
The ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions
The ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions Dr. Sven Bräunlich Department of Angiology University-Hospital Leipzig, Germany Disclosure Speaker
Dapagliflozin and Outcomes in Patients with Peripheral Artery Disease: Insights from DECLARE-TIMI 58
Dapagliflozin and Outcomes in Patients with Peripheral Artery Disease: Insights from DECLARE-TIMI 58 Marc P. Bonaca MD MPH for the DECLARE TIMI 58 Investigators American College of Cardiology March 2019
Clinico e Trattamento Post- Rivascolarizzazione Percutanea
Minicorso GISE: Interventistica per gli arti inferiori e per il piede diabetico Follow-up Clinico e Trattamento Post- Rivascolarizzazione Percutanea Giuseppe Biondi Zoccai Ospedale San Giovanni Battista
A new era in the treatment of peripheral artery disease (PAD)?
A new era in the treatment of peripheral artery disease (PAD)? Prof. Dr. Jan Beyer-Westendorf Head of Thrombosis Research, University Hospital Carl Gustav Carus, TU Dresden; Germany Senior Lecturer Thrombosis
Practical Point in Holistic Diabetic Foot Care 3 March 2016
Diabetic Foot Ulcer : Vascular Management Practical Point in Holistic Diabetic Foot Care 3 March 2016 Supapong Arworn, MD Division of Vascular and Endovascular Surgery Department of Surgery, Chiang Mai
The Fate of Unexpected Events Occurring in Standard EVAR
The Fate of Unexpected Events Occurring in Standard EVAR Andrea Stella Alma Mater Studiorum - University of Bologna Disclosure Speaker name: Prof. Andrea Stella I have the following potential conflicts
A multidisciplinary team approach for vascular disease: The role of cardiologists and vascular specialists
A multidisciplinary team approach for vascular disease: The role of cardiologists and vascular specialists Ana Paula Mollón MD Hospital Nacional A. Posadas Argentina Disclosure Speaker s name: Ana Paula
Hybrid Procedures for Peripheral Obstructive Disease - Step by Step -
Hybrid Procedures for Peripheral Obstructive Disease - Step by Step - Holger Staab, MD University Hospital Leipzig, Germany Clinic for Vascular Surgery Disclosure Speaker name:..holger Staab... I have
One Year after In.Pact Deep: Lessons learned from a failed trial. Prof. Dr. Thomas Zeller
One Year after In.Pact Deep: Lessons learned from a failed trial Prof. Dr. Thomas Zeller Disclosure Speaker name: Thomas Zeller... I have the following potential conflicts of interest to report: x Consulting:
Radiologic Evaluation of Peripheral Arterial Disease
January 2003 Radiologic Evaluation of Peripheral Arterial Disease Grace Tye, Harvard Medical School Year III Patient D.M. CC: 44 y/o male with pain in his buttocks Occurs after walking 2 blocks. Pain is
When to screen for PAD? Prof. Dr.Tine De Backer Prof. Dr. Jean-Claude Wautrecht
When to screen for PAD? Prof. Dr.Tine De Backer Prof. Dr. Jean-Claude Wautrecht How do we define asymptomatic PAD? A. ABI < 1 B. ABI < 0.9 C. ABI < 0.8 D. ABI > 1 How do we define asymptomatic PAD? A.
The present status of selfexpanding. for CLI: Why and when to use. Sean P Lyden MD Cleveland Clinic Cleveland, Ohio
The present status of selfexpanding and balloonexpandable tibial BMS and DES for CLI: Why and when to use Sean P Lyden MD Cleveland Clinic Cleveland, Ohio Disclosure Speaker name: Sean Lyden, MD I have
Endovascular treatment of severe TASC C and D external iliac artery occlusive disease. SAINT-LEBES Bertrand Toulouse FRANCE
Endovascular treatment of severe TASC C and D external iliac artery occlusive disease SAINT-LEBES Bertrand Toulouse FRANCE Disclosure Speaker name: SAINT-LEBES I have the following potential conflicts
Introduction to Peripheral Arterial Disease. Stacey Clegg, MD Interventional Cardiology August
Introduction to Peripheral Arterial Disease Stacey Clegg, MD Interventional Cardiology August 20 2014 Outline (and for the ABIM board exam * ** ***) Prevalence* Definitions Lower Extremity: Aorta*** Claudication***
Intercepting PAD. Playbook for Cardiovascular Care 2018 February 24, Jonathan D Woody, MD, FACS. University Surgical Vascular
Intercepting PAD Playbook for Cardiovascular Care 2018 February 24, 2018 Jonathan D Woody, MD, FACS University Surgical Vascular Attending Vascular Surgeon - Piedmont Athens Regional Adjunct Clinical Associate
Peripheral Arterial Disease Management A Practical Guide for Internists. EFIM Vascular Working Group
2 Peripheral Arterial Disease Management A Practical Guide for Internists EFIM Vascular Working Group 1 Peripheral arterial disease (PAD) is a growing concern among our aging population. More than 27 million
CRITICAL LIMB ISCHEMIA UNITED STATES EPIDEMIOLOGY TABLE OF CONTENTS
CRITICAL LIMB ISCHEMIA UNITED STATES EPIDEMIOLOGY TABLE OF CONTENTS CRITICAL LIMB ISCHEMIA... 1 CONCLUSION... 9 U.S. CRITICAL LIMB ISCHEMIA PREVALENCE... 9 MARKET OPPORTUNITY ENDOVASCULAR... 9 MARKET OPPORTUNITY
Steven Hadesman, MD Chief Medical Officer, MeridianRx Internal Medicine Physician, St. John Hospital
Steven Hadesman, MD Chief Medical Officer, MeridianRx Internal Medicine Physician, St. John Hospital Deep Venous Thrombosis Varicose Veins Venous insufficiency Phlebitis Lymphedema Elephantiasis nostras
Perfusion Assessment in Chronic Wounds
Perfusion Assessment in Chronic Wounds American Society of Podiatric Surgeons Surgical Conference September 22, 2018 Michael Maier, DPM, FACCWS Cardiovascular Medicine Cleveland Clinic Disclosures Speaker,
Intermittent Claudication (IC).
Intermittent Claudication (IC). The art of medicine consists of amusing the patient while nature takes its course. Voltaire - François-Marie Arouet (1694 1778) Claudication comes from the Latin word which
PROSPERO International prospective register of systematic reviews
PROSPERO International prospective register of systematic reviews Drug-eluting balloon angioplasty versus non-stenting balloon angioplasty for peripheral arterial disease of the lower limbs [Cochrane Protocol]
Diagnosis and Endovascular Treatment of Critical Limb Ischemia: What You Need to Know S. Jay Mathews, MD, MS, FACC
Diagnosis and Endovascular Treatment of Critical Limb Ischemia: What You Need to Know S. Jay Mathews, MD, MS, FACC Interventional Cardiologist/Endovascular Specialist Bradenton Cardiology Center Bradenton,
Imaging Strategy For Claudication
Who are the Debators? Imaging Strategy For Claudication Duplex Ultrasound Alone is Adequate to Select Patients for Endovascular Intervention - Pro: Dennis Bandyk MD No Disclosures PRO - Vascular Surgeon
PAD Characterization Within A Healthcare System" RAPID Face-to-Face Meeting Schuyler Jones, MD September 14, 2016
PAD Characterization Within A Healthcare System" RAPID Face-to-Face Meeting Schuyler, MD September 14, 2016 Interventional Cardiology and Cath Labs Disclosures Research Grants: Agency for Healthcare Research
PATIENT SPECIFIC STRATEGIES IN CRITICAL LIMB ISCHEMIA. Dr. Manar Trab Consultant Vascular Surgeon European Vascular Clinic DMCC Dubai, UAE
PATIENT SPECIFIC STRATEGIES IN CRITICAL LIMB ISCHEMIA Dr. Manar Trab Consultant Vascular Surgeon European Vascular Clinic DMCC Dubai, UAE Disclosure Speaker name: DR. Manar Trab I have the following potential
Step by step Hybrid procedures in peripheral obstructive disease. Holger Staab, MD University Hospital Leipzig, Germany Clinic for Vascular Surgery
Step by step Hybrid procedures in peripheral obstructive disease Holger Staab, MD University Hospital Leipzig, Germany Clinic for Vascular Surgery Disclosure Speaker name: H.H. Staab I have the following
- Lecture - Recommandations ESC : messages importants P. MEYER (Saint Laurent du Var) - Controverse - Qui doit faire l'angioplastie périphérique?
- Lecture - Recommandations ESC : messages importants P. MEYER (Saint Laurent du Var) - Controverse - Qui doit faire l'angioplastie périphérique? Un chirurgien E. DUCASSE (Bordeaux) Un interventionnel
How Do We Optimize the Medical Therapy of Patients with Critical Limb Ischemia?
How Do We Optimize the Medical Therapy of Patients with Critical Limb Ischemia? Ehrin J. Armstrong, MD MSc MAS Director, Interventional Cardiology Director, Vascular Laboratory VA Eastern Colorado Healthcare
ISR-treatment The Leipzig experience with purely mechanical debulking. Sven Bräunlich Department for Angiology University-Hospital Leipzig, Germany
ISR-treatment The Leipzig experience with purely mechanical debulking Sven Bräunlich Department for Angiology University-Hospital Leipzig, Germany Disclosure Speaker name: Sven Bräunlich I have the following
The relation of 2D perfusion angiography after BTK intervention and wound healing in patient with CLI - Single center prospective study -
The relation of 2D perfusion angiography after BTK intervention and wound healing in patient with CLI - Single center prospective study - Shinya Sasaki, MD. Saka General Hospital Miyagi, JAPAN Disclosure
Are DES and DEB worth the cost in BTK interventions?
Are DES and DEB worth the cost in BTK interventions? Thomas Zeller, MD University Heart-Center Freiburg-Bad Krozingen Bad Krozingen, Germany -1- My Disclosures: Advisory Board: Medtronic-Invatec, Gore,
Lower Extremity Peripheral Arterial Disease: Its All About the Pulse. Spence M Taylor, M.D.
Lower Extremity Peripheral Arterial Disease: Its All About the Pulse Spence M Taylor, M.D. President, Greenville Health System Clinical University Senior Associate Dean for Academic Affairs and Diversity
Peripheral Arterial Disease: Screening, Evaluation and Management. Mitchel Sklar, MD, FACC, FSCAI. Cardiovascular Associates of R.I.
Peripheral Arterial Disease: Screening, Evaluation and Management Mitchel Sklar, MD, FACC, FSCAI Cardiovascular Associates of R.I. Natural History of Intermittent Claudication/PAD: Peripheral to what?
Surgical Bypass vs. Zilver PTX stent for long SFA lesions : Interim results of the ZilverPass Trial
Surgical Bypass vs. Zilver PTX stent for long SFA lesions : Interim results of the ZilverPass Trial Dr. Koen Deloose Head of Vascular Surgery AZ Sint-Blasius Dendermonde Belgium Disclosure slide Speaker
The essentials for BTK procedures: wires, balloons, what else
A comprehensive approach to diabetic patient Tx The essentials for BTK procedures: wires, balloons, what else Dai-Do Do Clinical and Interventional Angiology Cardiovascular Department Disclosure Speaker
Hypothesis: When compared to conventional balloon angioplasty, cryoplasty post-dilation decreases the risk of SFA nses in-stent restenosis
Cryoplasty or Conventional Balloon Post-dilation of Nitinol Stents For Revascularization of Peripheral Arterial Segments Background: Diabetes mellitus is associated with increased risk of in-stent restenosis
Vascular Protection in Patients with CAD and PAD: New Options
Vascular Protection in Patients with CAD and PAD: New Options Professor Dr Eike Sebastian Debus Direktor Klinik für Gefäßmedizin Gefäßchirurgie Angiologie Interventionelle Therapie Deutsches Aortenzentrum
DCB use in fem-pop lesions of patients with CLI (RCC 4-5): subgroup analysis of IN.PACT Global 12-month outcomes
DCB use in fem-pop lesions of patients with CLI (RCC 4-5): subgroup analysis of IN.PACT Global 12-month outcomes Carlos Mena, MD FACC FSCAI Associate Professor of Medicine - Cardiology Director Cardiac
Angiosome concept myth or truth? Does it make a real difference in real world cases?
Angiosome concept myth or truth? Does it make a real difference in real world cases? Osamu Iida, MD, FACC Kansai Rosai Hospital Amagasaki, Hyogo, Japan Disclosure Speaker name:... I have the following
Massimiliano Fusaro, MD on behalf of ISAR-STATH Investigators. Deutsches Herzzentrum München, Technische Universität München Munich - Germany
Intravascular Stenting and Angiographic Results: Randomized Comparison of STenting, Stenting after Paclitaxel-eluting balloon and ATHerectomy in patients with symptomatic Peripheral Artery Disease - Results
Peripheral Arterial Disease. Westley Smith MD Vascular Fellow
Peripheral Arterial Disease Westley Smith MD Vascular Fellow Background (per 10,000) Goodney P, et al. Regional intensity of vascular care and lower extremity amputation rates. JVS. 2013; 6: 1471-1480.
Successful endovascular treatment using biopsy forceps for iliac artery stenosis with an organized thrombus
Successful endovascular treatment using biopsy forceps for iliac artery stenosis with an organized thrombus Taisuke Sato 1, Yasuhiro Takahashi 1, Kenta Onodera 1 Reiko Shiomura 1, Hiroki Goda 1, Isamu
DETECT-PAD Computerized and patient specific model to determine pressure gradients in borderline iliac artery stenosis with MRA/ CTA
DETECT-PAD Computerized and patient specific model to determine pressure gradients in borderline iliac artery stenosis with MRA/ CTA Jean-Paul P.M. de Vries Head Department of Surgery University Medical
Evolving Challenges in the Evaluation and Treatment of Lower Extremity PAD -- The Peripheral Academic Research Consortium (PARC)
Evolving Challenges in the Evaluation and Treatment of Lower Extremity PAD -- The Peripheral Academic Research Consortium (PARC) W. Schuyler Jones, MD FACC Director, Adult Cardiac Catheterization Laboratory
Wifi classification does not predict limb amputation risk in dialysis patients following critical limb ischemia revascularization
Wifi classification does not predict limb amputation risk in dialysis patients following critical limb ischemia revascularization A Sonetto, M Abualhin, M Gargiulo, GL Faggioli, A Stella Disclosure Speaker
The ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions Preliminary report
The ZILVERPASS study a randomized study comparing ZILVER PTX stenting with Bypass in femoropopliteal lesions Preliminary report G. Biro, M. Bosiers on behalf of ZILVERPASS Study Group Disclosure Speaker
9/7/2018. Disclosures. CV and Limb Events in PAD. Challenges to Revascularization. Challenges. Answering the Challenge
Disclosures State-of-the-Art Endovascular Lower Extremity Revascularization Promotional Speaker Jansen Pharmaceutical Promotional Speaker Amgen Pharmaceutical C. Michael Brown, MD, FACC al Cardiology Associate
Chimney technique combined with aortoiliac stenting for the treatment. disease. of juxtarenal aortoiliac occlusive
Chimney technique combined with aortoiliac stenting for the treatment of juxtarenal aortoiliac occlusive disease Suwanruangsri Veera,MD Kaviros Pruesttipong,MD Department of Surgery, Maharat Nakhon Ratchasima
Extreme SFA Lesions: DETOUR I 12- Month Results in Lesions >30cm. Sean Lyden, MD Chairman Vascular Surgery Cleveland Clinic Cleveland, Ohio
Extreme SFA Lesions: DETOUR I 12- Month Results in Lesions >30cm Sean Lyden, MD Chairman Vascular Surgery Cleveland Clinic Cleveland, Ohio Extreme SFA Lesions: DETOUR I 12-Month Results in Lesions >30cm
Management of Stable Ischemic Heart Disease. Vinay Madan MD February 10, 2018
Management of Stable Ischemic Heart Disease Vinay Madan MD February 10, 2018 1 Disclosure No financial disclosure. 2 Overview of SIHD Diagnosis Outline of talk Functional vs. Anatomic assessment Management
Do we really need a stent in long SFA lesions? No: DEB is the answer
Do we really need a stent in long SFA lesions? No: DEB is the answer Thomas Zeller, MD University Heart-Center Freiburg-Bad Krozingen Bad Krozingen Germany My Disclosures: Advisory Board: Medtronic-Invatec,
DCB level 1 evidence review
DCB level 1 evidence review Raphaël COSCAS Vascular Surgery Department Ambroise Paré Hospital, AP-HP and Paris-Ouest University Boulogne-Billancourt, France Disclosure Speaker name: Raphael COSCAS I have
PRISM Trial. Retrospective Case Review of Technical Success Using the Penumbra and Indigo Systems for Mechanical Thrombectomy in the Periphery
PRISM Trial Retrospective Case Review of Technical Success Using the Penumbra and Indigo Systems for Mechanical Thrombectomy in the Periphery George L. Adams, MD, MHS, FACC, FSCAI Clinical Associate Professor
Peripheral Arterial Disease: Who has it and what to do about it?
Peripheral Arterial Disease: Who has it and what to do about it? Seth Krauss, M.D. Alaska Annual Nurse Practitioner Conference September 16, 2011 Scope of the Problem Incidence: 20%